Should I buy Genpact (G) stock or is it too late?

Genpact · Industrials · price $38
Logo GenpactSee the full Genpact (G) profile
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Baird68% of its targets hit on this sector (322 calls tested). It aims for $38 (+1.3 %), call made on July 8, 2026, maturing on July 8, 2027 (51 d ago).

The 6 reliable analysts $40.50+8.0 %
The 1 other firm $39+3.9 %
How to read it: the 6 reliable firms are not filtered by optimism — 4 aim above the price, 2 below, hence their $40.50 median. “The 1 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Genpact

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.
Firm% rightGain vs sectorCallsAims for
Needham45 %+8.1 %20$45 +20%
Citigroup58 %+6.3 %12$36 -4%
JP Morgan33 %-7.8 %9$45 +20%
In short — Should you invest in Genpact? Is it too late, still worth it? Analysts are split (29% buy, median target $39, i.e. +4%). We give you both sides, with the numbers — not advice.

✅ Reasons to believe

  • Pays a dividend (1.9% yield) — regular income on top of potential upside.

⚠️ Reasons to hesitate

  • Even the most reliable firm on G, Citigroup (58% hit rate, 12 scored calls), only targets $36 (call made on August 7, 2026, maturing on August 7, 2027) (-4%) in its most recent call, and $43 (call made on October 23, 2025, maturing on October 23, 2026) (+15%) in the one coming due soonest. The stock may already have run past its target.
  • The consensus is not unanimous: of 7 ratings, 5 are neutral.
  • Limited upside: the median target is only +4% from the current price.
  • A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on G

Median target $39 (+4%) · 7 ratings · Hold consensus

Strong Buy00%
Buy229%
Hold571%
Sell00%
Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Genpact now?

We won't decide for you. The facts: 29% of analysts rate it a buy, median target $39 (+4%), and Citigroup (most reliable on G, 58%) targets $36. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Genpact?

Not according to analysts: the median target ($39) is still +4% above the current price ($38) (most reliable on G: Citigroup, 58%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Genpact still worth investing in?

It depends on the gap between the price ($38) and its estimated value: analysts target $39 on median (+4%), with 29% buys (most reliable on G: Citigroup, 58%). Cross-check with their real reliability on G and the cautions above. Information, not advice.

What's the main risk in buying G?

Even the most reliable firm on G, Citigroup (58% hit rate, 12 scored calls), only targets $36 (call made on August 7, 2026, maturing on August 7, 2027) (-4%) in its most recent call, and $43 (call made on October 23, 2025, maturing on October 23, 2026) (+15%) in the one coming due soonest. The stock may already have run past its target.

→ Go deeper: the full Genpact profile (consensus, analyst reliability, price target, performance).

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)